Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-23-005517
Filing Date
2023-04-06
Accepted
2023-04-06 07:02:09
Documents
6
Period of Report
2023-05-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20230519xdef14a.htm DEF 14A 685846
2 GRAPHIC tmb-20230519xdef14a001.jpg GRAPHIC 12602
3 GRAPHIC tmb-20230519xdef14a002.jpg GRAPHIC 4394
4 GRAPHIC tmb-20230519xdef14a004.jpg GRAPHIC 203288
5 GRAPHIC tmb-20230519xdef14a005.jpg GRAPHIC 255178
6 GRAPHIC tmb-20230519xdef14a006.jpg GRAPHIC 266093
  Complete submission text file 0001558370-23-005517.txt   1708649
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39746 | Film No.: 23804361
SIC: 2834 Pharmaceutical Preparations